Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23494714 | 1.00 | GLA (0.57) | GLAHSD17B10RXRARXRBRXRG | |
| SCHEMBL23494665 | 1.00 | GLA (0.57) | GLAHSD17B10RXRARXRBRXRG | |
| SCHEMBL23494701 | 1.00 | GLA (0.57) | GLAHSD17B10RXRARXRBRXRG | |
| SCHEMBL23494739 | 0.92 | GLA (0.49) | GLAHSD17B10RXRARXRBRXRG | |
| SCHEMBL23494674 | 0.92 | GLA (0.49) | GLAHSD17B10RXRARXRBRXRG | |
| SCHEMBL23494755 | 0.92 | GLA (0.49) | GLAHSD17B10RXRARXRBRXRG | |
| SCHEMBL23494704 | 0.92 | GLA (0.49) | GLAHSD17B10RXRARXRBRXRG | |
| SCHEMBL23494747 | 0.92 | GLA (0.49) | GLAHSD17B10RXRARXRBRXRG | |
| SCHEMBL23494707 | 0.92 | GLA (0.49) | GLAHSD17B10RXRARXRBRXRG | |
| SCHEMBL23494670 | 0.92 | GLA (0.49) | GLAHSD17B10RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4317128-B1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & CO (US) | 2025-07-23 | — | — | EP | claimed |
| US-12358864-B2 | Trisamide compounds and compositions comprising the same | MILLIKEN & COMPANY (US) | 2025-07-15 | — | — | US | claimed |
| CN-117756661-A | Triamide compound and composition comprising same | 美利肯公司 | 2024-03-26 | — | — | CN | claimed |
| EP-4317128-A2 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | Milliken & Company (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4073029-B1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & CO (US) | 2024-01-31 | — | — | EP | claimed |
| CN-115066413-B | Triamide compound and composition comprising same | 美利肯公司 | 2024-01-09 | — | — | CN | claimed |
| US-20230331660-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY | 2023-10-19 | — | — | US | claimed |
| US-11724983-B2 | Trisamide compounds and compositions comprising the same | MILLIKEN & COMPANY (US) | 2023-08-15 | — | — | US | claimed |
| EP-4073029-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | Milliken & Company (US) | 2022-10-19 | — | — | EP | claimed |
| CN-115066413-A | Triamide compounds and compositions comprising the same | 美利肯公司 | 2022-09-16 | — | — | CN | claimed |
| US-20210179540-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY | 2021-06-17 | — | — | US | claimed |
| WO-2021119633-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY (US) | 2021-06-17 | — | — | WO | claimed |
| EP-4317128-B1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & CO (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12358864-B2 | Trisamide compounds and compositions comprising the same | MILLIKEN & COMPANY (US) | 2025-07-15 | — | — | US | disclosed |
| CN-117756661-A | Triamide compound and composition comprising same | 美利肯公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4317128-A2 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | Milliken & Company (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4073029-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | Milliken & Company (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-115066413-A | Triamide compounds and compositions comprising the same | 美利肯公司 | 2022-09-16 | — | — | CN | disclosed |
| US-20210179540-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY | 2021-06-17 | — | — | US | disclosed |
| WO-2021119633-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | MILLIKEN & COMPANY (US) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724983-B2 | Trisamide compounds and compositions comprising the same | PTAR1, TIPRL, TCOF1 | GLA 612/4885HSD17B10 3171/4885RXRA 2448/4885 |
| US-20230331660-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | PTAR1, TIPRL, TCOF1 | GLA 612/4885HSD17B10 3171/4885RXRA 2448/4885 |
| US-20210179540-A1 | TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | PTAR1, TIPRL, TCOF1 | GLA 612/4885HSD17B10 3171/4885RXRA 2448/4885 |
| US-12358864-B2 | Trisamide compounds and compositions comprising the same | PTAR1, TIPRL, TCOF1 | GLA 612/4885HSD17B10 3171/4885RXRA 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.